GAIA and MEDICE sign deal for commercialization of attexis for ADHD in Germany

14 November 2024

Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis® with fellow German firm MEDICE Arzneimittel Pütter.

As one of the leading pharma companies in ADHD, the MEDICE Health Family will use its market know-how and its commercial scale to bring attexis to patients in Germany.

attexis is a personalized, fully-automated digital therapy designed to help adult ADHD patients better manage their symptoms. Its efficacy and safety are currently being studied in a large-scale clinical trial.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK